Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist
GA-3
1 other identifier
interventional
18
1 country
1
Brief Summary
Delinieation of GIP's effects during an oral glucose tolerance test (OGTT) in humans using GIP receptor antagonisation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Mar 2017
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2017
CompletedFirst Submitted
Initial submission to the registry
April 25, 2017
CompletedFirst Posted
Study publicly available on registry
April 28, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2017
CompletedNovember 1, 2017
October 1, 2017
4 months
April 25, 2017
October 30, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Insulin levels
Serum insulin AUC (area under the curve)
240 minutes
Study Arms (4)
Placebo
PLACEBO COMPARATORSaline
GIP-A
OTHERInfusion of GIP-A alone as study tool.
GLP-1 receptor antagonist Exendin[9-39]
OTHERInfusion of GLP-1 receptor antagonist Exendin\[9-39\] alone as study tool.
GIP-A + Exendin[9-39]
OTHERInfusion of GIP-A + GLP-1 receptor antagonist Exendin\[9-39\] together as study tools.
Interventions
Exendin\[9-39\]
Eligibility Criteria
You may qualify if:
- Normal kidney function, liver function and hemoglobin levels.
You may not qualify if:
- Medication, Diabetes type 1 or 2, first degree relatives with Diabetes type 2
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Center for Diabetes Research
Gentofte Municipality, Copenhagen, 2900, Denmark
Related Publications (2)
Helsted MM, Gasbjerg LS, Lanng AR, Bergmann NC, Stensen S, Hartmann B, Christensen MB, Holst JJ, Vilsboll T, Rosenkilde MM, Knop FK. The role of endogenous GIP and GLP-1 in postprandial bone homeostasis. Bone. 2020 Nov;140:115553. doi: 10.1016/j.bone.2020.115553. Epub 2020 Jul 27.
PMID: 32730920DERIVEDGasbjerg LS, Helsted MM, Hartmann B, Jensen MH, Gabe MBN, Sparre-Ulrich AH, Veedfald S, Stensen S, Lanng AR, Bergmann NC, Christensen MB, Vilsboll T, Holst JJ, Rosenkilde MM, Knop FK. Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals. Diabetes. 2019 May;68(5):906-917. doi: 10.2337/db18-1123. Epub 2019 Jan 9.
PMID: 30626611DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Filip K Knop, MD, PhD
UHGentofte, Center for Diabetes Research
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD
Study Record Dates
First Submitted
April 25, 2017
First Posted
April 28, 2017
Study Start
March 1, 2017
Primary Completion
July 1, 2017
Study Completion
July 1, 2017
Last Updated
November 1, 2017
Record last verified: 2017-10
Data Sharing
- IPD Sharing
- Will not share